Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) – Expanded indication
February 26, 2024 - Gilead announced the FDA approval of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.
Top